Biodesix Inc.

BDSX

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001439725

C

middle fifth of 367 graded peers in healthcare

rank 181 of 367; percentile 49.2; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise




Scoreboard	
Profitability	B percentile 34.0
Solvency	C/D percentile 61.3
Growth and financing	C percentile 48.8
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $87.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 261 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$9.93 2026-11-13; market equity $110.1M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Biodesix, Inc. ("Biodesix", "we," "us," "our" or the "Company") is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 34.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(13.0%)	(6.6%)		34.0	799	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 61.3						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(19.59)	(0.31)		73.6	743	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	(3.61x)	(4.51x)		36.4	78	2025-12-31
Current ratio	1.86x	2.96x		74.0	825	2025-12-31
Growth and financing, sleeve percentile 48.8						
Revenue growth, three-year compound	32.3%	10.1%		20.0	411	2025-12-31
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(2.0%)	2.3%		56.4	693	2025-12-31
Net share issuance, one year	35.1%	2.4%		70.0	627	2026-02-20


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 35.1%

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
176	ClearPoint Neuro, Inc. (CLPT)	47.8	C	
177	ImmunityBio, Inc. (IBRX)	48.1	C	short runway, distress
178	Scynexis Inc. (SCYX)	48.4	C	fortress balance sheet
179	Amneal Pharmaceuticals, Inc. (AMRX)	48.6	C	
180	Macrogenics Inc. (MGNX)	48.9	C	
181	Biodesix Inc. (BDSX)	49.2	C	dilution
182	Savara Inc. (SVRA)	49.5	C	short runway, fortress balance sheet
183	UroGen Pharma Ltd. (URGN)	49.7	C	distress
184	Evolus, Inc. (EOLS)	50.0	C	
185	Neogen Corp. (NEOG)	50.3	C	late filer
186	Neuroone Medical Technologies Corp. (NMTC)	50.5	C	short runway, fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	336.7%	(1.5%)	98
Distance from 52-week high	(67.7%)	(32.0%)	15
EBIT to enterprise value	(21.3%)	(1.8%)	25
Free cash flow yield	(21.5%)	(1.0%)	23
Book value to price	0.08	0.29	21
Sales to price	0.81	0.29	78
Composite equity issuance, five years	212.2%	19.1%	89
Relative strength against the sector, log excess return	1.31	(0.18)	98

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$28.4M
Operating cash flow, four quarters	-$18.2M
Months of runway	18.8
Days since last periodic filing	9 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$2.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$35.3M	2025-12-31	2026-02-26	10-K	26-076547
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$23.3M	2025-12-31	2026-02-26	10-K	26-076547
3	assets	us-gaap:Assets	$87.5M	2025-12-31	2026-02-26	10-K	26-076547
4	assets	us-gaap:Assets	$97.2M	2024-12-31	2026-02-26	10-K	26-076547
5	current assets	us-gaap:AssetsCurrent	$32.5M	2025-12-31	2026-02-26	10-K	26-076547
6	current liabilities	us-gaap:LiabilitiesCurrent	$17.4M	2025-12-31	2026-02-26	10-K	26-076547
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$497.8M	2025-12-31	2026-02-26	10-K	26-076547
8	operating income	us-gaap:OperatingIncomeLoss	-$27.9M	2025-12-31	2026-02-26	10-K	26-076547
9	book equity	us-gaap:StockholdersEquity	-$2.5M	2025-12-31	2026-02-26	10-K	26-076547
10	liabilities	us-gaap:Liabilities	$89.9M	2025-12-31	2026-02-26	10-K	26-076547
11	interest expense	us-gaap:InterestExpense	$7.7M	2025-12-31	2026-02-26	10-K	26-076547
12	revenue	us-gaap:Revenues	$88.5M	2025-12-31	2026-02-26	10-K	26-076547
13	revenue	us-gaap:Revenues	$71.3M	2024-12-31	2026-02-26	10-K	26-076547
14	revenue	us-gaap:Revenues	$49.1M	2023-12-31	2025-03-03	10-K	25-030835
15	revenue	us-gaap:Revenues	$38.2M	2022-12-31	2024-03-01	10-K	24-023513
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$259,000	2025-12-31	2026-02-26	10-K	26-076547
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$48.6M	2024-12-31	2026-02-26	10-K	26-076547
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.2M	2024-12-31	2026-02-26	10-K	26-076547

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$22.9M	2023-12-31	2025-03-03	10-K	25-030835
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$22.9M	2023-12-31	2025-03-03	10-K	25-030835
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$45.0M	2022-12-31	2024-03-01	10-K	24-023513
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.3M	2022-12-31	2024-03-01	10-K	24-023513
23	assets	us-gaap:Assets	$99.1M	2023-12-31	2025-03-03	10-K	25-030835
24	assets	us-gaap:Assets	$92.9M	2022-12-31	2024-03-01	10-K	24-023513
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	9,858,358	2026-02-20	2026-02-26	10-K	26-076547
26	shares outstanding	dei:EntityCommonStockSharesOutstanding	145,978,410	2025-02-24	2025-03-03	10-K	25-030835

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.